Literature DB >> 23320755

Reduced expression of BTBD10 in anterior horn cells with Golgi fragmentation and pTDP-43-positive inclusions in patients with sporadic amyotrophic lateral sclerosis.

Natsumi Furuta1, Kouki Makioka, Yukio Fujita, Masaki Ikeda, Masamitsu Takatama, Masaaki Matsuoka, Koichi Okamoto.   

Abstract

Overexpression of BTBD10 (BTB/POZ domain-containing protein 10) suppresses G93A-superoxide dismutase 1 (SOD1)-induced motor neuron death in a cell-based amyotrophic lateral sclerosis (ALS) model. In the present study, paraffin sections of spinal cords from 13 patients with sporadic ALS and 10 with non-ALS disorders were immunostained using a polyclonal anti-BTBD10 antibody. Reduced BTBD10 expression in the anterior horn cells was more frequent in spinal cords from ALS patients than in cords from patients with non-ALS disorders. We further investigated the relationship between the level of BTBD10 immunoreactivity and the morphology of the Golgi apparatus (GA) and the presence of phosphorylated TAR-DNA-binding protein 43 (pTDP-43). Mirror sections of spinal cords from five sporadic ALS cases were immunostained with antibodies against BTBD10 and trans-Golgi-network (TGN)-46 or pTDP-43. Whereas 89.7-96.5% of the neurons with normal BTBD10 immunoreactivity showed normal GA morphology and no pTDP-43 cytoplasmic aggregates, 86.2-94.3% of the neurons with reduced BTBD10 expression showed GA fragmentation and abnormal pTDP-43 aggregates. These findings suggest that reduced BTBD10 expression is closely linked to the pathogenesis of sporadic ALS.
© 2013 Japanese Society of Neuropathology.

Entities:  

Keywords:  ALS; BTBD10; Golgi apparatus; pTDP-43; pathology

Mesh:

Substances:

Year:  2013        PMID: 23320755     DOI: 10.1111/neup.12010

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  4 in total

1.  Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Kathleen N Moore; David Tritchler; Kenneth M Kaufman; Heather Lankes; Michael C J Quinn; Linda Van Le; Andrew Berchuck; Floor J Backes; Krishnansu S Tewari; Roger B Lee; Joshua P Kesterson; Robert M Wenham; Deborah K Armstrong; Thomas C Krivak; Michael A Bookman; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2017-09-19       Impact factor: 5.482

2.  KCTD20, a relative of BTBD10, is a positive regulator of Akt.

Authors:  Mikiro Nawa; Masaaki Matsuoka
Journal:  BMC Biochem       Date:  2013-10-24       Impact factor: 4.059

Review 3.  KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders.

Authors:  Xinchen Teng; Abdel Aouacheria; Loïc Lionnard; Kyle A Metz; Lucian Soane; Atsushi Kamiya; J Marie Hardwick
Journal:  CNS Neurosci Ther       Date:  2019-07       Impact factor: 5.243

4.  BTBD10 inhibits glioma tumorigenesis by downregulating cyclin D1 and p-Akt.

Authors:  Yu Liu; Sen Li; Ruoping Chen; Juxiang Chen; Bo Xiao; Yicheng Lu; Jiangang Liu
Journal:  Open Life Sci       Date:  2022-08-10       Impact factor: 1.311

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.